Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Elevated bone remodeling markers of CTX and P1NP in addition to sclerostin in patients with X-linked hypophosphatemia: A Cross-Sectional Controlled Study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Multiple Fractures and Impaired Bone Fracture Healing in a Patient with Pycnodysostosis and Hypophosphatasia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Chronic Non-bacterial Osteomyelitis: A Review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Bone mass development in childhood and its association with physical activity and vitamin D levels. The CHAMPS-Study DK

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The effect of 4 months exercise training on systemic biomarkers of cartilage and bone turnover in hip osteoarthritis patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Aspects of bone remodeling have only been scarcely studied in X-linked hypophosphatemia (XLH). In this cross-sectional controlled study, we assessed biochemical indices of bone remodeling and sclerostin in 27 adult patients (median age 47 [range 24-79] years, 19 women, 8 men) with XLH matched with 81 healthy control subjects (1:3) with respect to age-, sex-, and menopausal status. Markers of bone resorption (carboxyterminal cross-linked telopeptide of type 1 collagen, CTX) and formation (N-terminal propeptide of type 1 procollagen, P1NP) were higher in XLH patients compared to controls (median [IQR] 810 [500-1340] vs 485 [265-715] ng/l and 90 [57-136] vs 49 [39-65] ug/l, respectively, both p < 0.001) as well as sclerostin (0.81 [0.60-1.18] vs 0.54 [0.45-0.69] ng/ml, p < 0.001). Similar differences were found when comparing currently treated (with phosphate and alfacalcidol) (n = 11) and untreated (n = 16) XLH patients with their respective controls. We found no significant associations with treatment status and indices of bone remodeling or sclerostin although sclerostin tended to be increased in untreated versus treated (p = 0.06). In contrast to previous histomorphometric studies suggesting a low remodeling activity in XLH, these biochemical indices suggest high osteoblast and osteoclast activity. Further studies are needed to ascertain if the higher sclerostin level in XLH is related to osteocyte dysfunction or represents a secondary phenomenon.

Original languageEnglish
JournalCalcified Tissue International
Volume104
Issue number6
Pages (from-to)591-598
Number of pages8
ISSN0171-967X
DOIs
Publication statusPublished - Jun 2019

ID: 58197273